MCM
BEAM icon

MAI Capital Management’s Beam Therapeutics BEAM Stock Holding History

MAI Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-659
Closed -$15.7K – 2351
2026
Q1 		$15.7K Buy
659
+14
+2% +$388 ﹤0.01% 2924
2025
Q4 		$17.9K Hold
645
– – ﹤0.01% 2572
2025
Q3 		$15.7K Hold
645
– – ﹤0.01% 2523
2025
Q2 		$11K Sell
645
-15
-2% -$261 ﹤0.01% 2679
2025
Q1 		$12.9K Hold
660
– – ﹤0.01% 2382
2024
Q4 		$16.4K Buy
+660
New +$16.8K ﹤0.01% 2308

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

MAI Capital Management's BEAM Position: Q2 2026 in Review

MAI Capital Management sold out of Beam Therapeutics (BEAM) in Q2 2026, closing a stake of 659 shares — an estimated $15.7K sold.

MAI Capital Management first reported a position in BEAM in Q4 2024 and held it in 6 quarters. The position peaked at $17.9K in Q4 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • MAI Capital Management reported no remaining Beam Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 659 Beam Therapeutics shares in Q2 2026, an estimated $15.7K.
  • MAI Capital Management first reported a position in Beam Therapeutics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Beam Therapeutics position peaked at $17.9K in Q4 2025.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.